Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
Authors
Keywords
-
Journal
Current Neurology and Neuroscience Reports
Volume 21, Issue 7, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-19
DOI
10.1007/s11910-021-01117-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis
- (2021) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment
- (2021) Susana Otero-Romero et al. Expert Review of Clinical Immunology
- Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
- (2021) Arpan Patel et al. JAMA Neurology
- Mild or Moderate Covid-19
- (2020) Rajesh T. Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Chronic Hepatitis B Virus Infection in the United States
- (2020) Joseph K. Lim et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Hepatitis B Virus Reactivation Potentiated by Biologics
- (2020) Eiichi Ogawa et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Herpesvirus Infections Potentiated by Biologics
- (2020) Dora Y. Ho et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
- (2020) Céline Louapre et al. JAMA Neurology
- Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab
- (2020) Michael Auer et al. Multiple Sclerosis and Related Disorders
- Serious safety events in rituximab‐treated multiple sclerosis and related disorders
- (2020) Brandi L. Vollmer et al. Annals of Clinical and Translational Neurology
- Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
- (2020) Adil Maarouf et al. Neurology-Neuroimmunology & Neuroinflammation
- COVID-19 outcomes in MS
- (2020) Erica Parrotta et al. Neurology-Neuroimmunology & Neuroinflammation
- Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis
- (2020) Clara Grazia Chisari et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
- (2020) Lucia Moiola et al. Multiple Sclerosis Journal
- Effects of MS disease-modifying therapies on responses to vaccinations: A review.
- (2020) John Robert Ciotti et al. Multiple Sclerosis and Related Disorders
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis
- (2019) Bruce A. Cohen NEUROLOGY
- Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis
- (2019) Sudhir Kumar Yadav et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date
- (2019) Mihai Ancau et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate
- (2019) Cristina Scarpazza et al. Multiple Sclerosis Journal
- Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
- (2019) Lana Zhovtis Ryerson et al. NEUROLOGY
- Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis
- (2019) Meng-Chuan Lu et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
- (2019) Gustavo Luna et al. JAMA Neurology
- Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
- (2018) Antonio Riccardo Buonomo et al. Expert Opinion On Drug Safety
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- Progressive multifocal leukoencephalopathy after fingolimod treatment
- (2018) Joseph R. Berger et al. NEUROLOGY
- Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View
- (2018) Elizabeth A. Mills et al. Frontiers in Immunology
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
- (2018) Kathleen L. Dooling et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management
- (2018) David J Epstein et al. Open Forum Infectious Diseases
- Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients
- (2018) Ursela Baber et al. JOURNAL OF NEUROLOGY
- Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient
- (2018) Paola Perini et al. Multiple Sclerosis and Related Disorders
- Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
- (2018) Gisa Ellrichmann et al. JOURNAL OF NEUROLOGY
- Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis
- (2018) Maria R Ciardi et al. Open Forum Infectious Diseases
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Natalizumab-associated PML
- (2017) Nicholas Schwab et al. NEUROLOGY
- Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies
- (2017) Eric M. L. Williamson et al. Neurotherapeutics
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis
- (2017) Keh Yann et al. Multiple Sclerosis and Related Disorders
- The Prevalence of Latent Tuberculosis Infection in the United States
- (2016) James D. Mancuso et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- ECIL guidelines for preventingPneumocystis jiroveciipneumonia in patients with haematological malignancies and stem cell transplant recipients
- (2016) Johan Maertens et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Extended interval dosing of natalizumab in multiple sclerosis
- (2016) L Zhovtis Ryerson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Effect of teriflunomide on QuantiFERON-TB Gold results
- (2016) Alessandra Bua et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Long-term safety and efficacy of teriflunomide
- (2016) Paul O'Connor et al. NEUROLOGY
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease
- (2015) Darren M. Roberts et al. JOURNAL OF AUTOIMMUNITY
- A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation
- (2015) Peter G. E. Kennedy et al. JOURNAL OF GENERAL VIROLOGY
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
- (2015) Nature Reviews Neurology
- Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
- (2015) L. Kappos et al. NEUROLOGY
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
- (2015) Himal Lal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Varicella-Zoster Virus Infections in Patients Treated With Fingolimod
- (2015) Ann M. Arvin et al. JAMA Neurology
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
- (2014) Amit Bar-Or et al. DRUGS
- Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
- (2014) Wai-Kay Seto et al. JOURNAL OF CLINICAL ONCOLOGY
- Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
- (2014) Michael Kaufman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
- (2012) Carla Casulo et al. Clinical Lymphoma Myeloma & Leukemia
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group
- (2012) Seok Jin Kim et al. LEUKEMIA & LYMPHOMA
- Humoral immune response to influenza vaccine in natalizumab-treated MS patients
- (2012) Mattias Vågberg et al. NEUROLOGICAL RESEARCH
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
- (2010) J.-E. Gottenberg et al. ARTHRITIS AND RHEUMATISM
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
- (2010) Maura L. Gillison et al. CANCER
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
- (2010) C. Ford et al. Multiple Sclerosis Journal
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
- (2008) Winnie Yeo et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started